Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
06/23/2021
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Patterns and Predictors of First-Line Maintenance Therapy Use in Ovarian Cancer
06/23/2021
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Physician- and Patient-Reported Outcomes Among Five Radiotherapy Methods for Prostate Cancer
06/21/2021
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing...
06/21/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Clinical and Economic Burden of First-Line Chemoimmunotherapy for CLL/SLL
06/21/2021
Between high-risk and nonhigh-risk patients with CLL or SLL initiating first-line chemoimmunotherapy, high-risk patients experience greater risk of next treatment or death, treatment failure, and higher costs.
Between high-risk and nonhigh-risk patients with CLL or SLL initiating first-line chemoimmunotherapy, high-risk patients experience greater risk of next treatment or death, treatment failure, and higher costs.
Between high-risk and...
06/21/2021
Journal of Clinical Pathways
Conference Coverage
Real-World First-Line Treatment Patterns in Commercially Insured Patients With CSPC
06/17/2021
A majority of commercially insured and Medicare patients with metastatic castration-sensitive prostate cancer may not be receiving optimal life-prolonging therapies.
A majority of commercially insured and Medicare patients with metastatic castration-sensitive prostate cancer may not be receiving optimal life-prolonging therapies.
A majority of commercially...
06/17/2021
Journal of Clinical Pathways
Conference Coverage
An International Analysis of Treatments and Outcomes Among Patients with Epithelial Ovarian Cancer
06/17/2021
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation...
06/17/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with...
06/14/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.
In a large representative sample...
06/14/2021
Journal of Clinical Pathways
Conference Coverage
Cost Analysis of Biosimilar vs Reference Rituximab for Treating CLL and Other Diseases
06/10/2021
Rituximab-abbs may have more economic benefits compared to reference rituximab in patients with NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Rituximab-abbs may have more economic benefits compared to reference rituximab in patients with NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Rituximab-abbs may have more...
06/10/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-World PARP Inhibitor Toxicities in Ovarian Cancer Consistent With Clinical Trials
06/07/2021
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice,...
06/07/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use